{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:01:20Z","timestamp":1790787680317,"version":"4.1.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007543","name":"National Agency for Safety of Medicines and Health Products","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007543","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ophthalmologyscience.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology Science"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.xops.2026.101371","type":"journal-article","created":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:17:20Z","timestamp":1787008640000},"page":"101371","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Neurodevelopmental Disorders in Infants Treated with Anti-VEGF Agents versus Laser Photocoagulation or Cryotherapy for Retinopathy of Prematurity"],"prefix":"10.1016","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4002-7414","authenticated-orcid":false,"given":"In\u00e8s","family":"Ben Ghezala","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Bonnet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Conese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Hassine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxime","family":"Luu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Creuzot-Garcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0028-1837","authenticated-orcid":false,"given":"Marc","family":"Bardou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.xops.2026.101371_bib1","doi-asserted-by":"crossref","first-page":"35","DOI":"10.5409\/wjcp.v5.i1.35","article-title":"Retinopathy of prematurity: past, present and future","volume":"5","author":"Shah","year":"2016","journal-title":"World J Clin Pediatr"},{"issue":"11","key":"10.1016\/j.xops.2026.101371_bib2","article-title":"A review on the incidence and related risk factors of retinopathy of prematurity across various countries","volume":"14","author":"Nair","year":"2022","journal-title":"Cureus"},{"issue":"7","key":"10.1016\/j.xops.2026.101371_bib3","doi-asserted-by":"crossref","first-page":"553","DOI":"10.3928\/23258160-20170630-06","article-title":"The epidemiology of retinopathy of prematurity in the United States","volume":"48","author":"Ludwig","year":"2017","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"issue":"2","key":"10.1016\/j.xops.2026.101371_bib4","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/aos.13549","article-title":"Increased frequency of retinopathy of prematurity over the last decade and significant regional differences","volume":"96","author":"Holmstr\u00f6m","year":"2018","journal-title":"Acta Ophthalmol"},{"issue":"2","key":"10.1016\/j.xops.2026.101371_bib5","article-title":"Peripheral retinal ablation for threshold retinopathy of prematurity in preterm infants","volume":"1999","author":"Andersen","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"10.1016\/j.xops.2026.101371_bib6","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1001\/archophthalmol.2011.143","article-title":"Grating visual acuity results in the early treatment for retinopathy of prematurity study","volume":"129","author":"Dobson","year":"2011","journal-title":"Arch Ophthalmol"},{"issue":"7","key":"10.1016\/j.xops.2026.101371_bib7","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1007374","article-title":"Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity","volume":"364","author":"Mintz-Hittner","year":"2011","journal-title":"N Engl J Med"},{"issue":"10208","key":"10.1016\/j.xops.2026.101371_bib8","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S0140-6736(19)31344-3","article-title":"Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial","volume":"394","author":"Stahl","year":"2019","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.xops.2026.101371_bib9","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1001\/jama.2022.10564","article-title":"Effect of intravitreal aflibercept vs laser photocoagulation on treatment success of retinopathy of prematurity: the FIREFLEYE randomized clinical trial","volume":"328","author":"Stahl","year":"2022","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.xops.2026.101371_bib10","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1053\/j.semperi.2019.05.011","article-title":"Anti-vascular endothelial growth factor intravitreal therapy for retinopathy of prematurity","volume":"43","author":"VanderVeen","year":"2019","journal-title":"Semin Perinatol"},{"issue":"1","key":"10.1016\/j.xops.2026.101371_bib11","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1111\/aos.17541","article-title":"Impact of anti-VEGF therapy versus laser therapy on mortality and treatment outcomes in retinopathy of prematurity: a systematic review and meta-analysis","volume":"104","author":"Wang","year":"2026","journal-title":"Acta Ophthalmol"},{"issue":"5","key":"10.1016\/j.xops.2026.101371_bib12","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1007\/s40123-023-00744-7","article-title":"Laser versus Anti-VEGF: a paradigm shift for treatment-warranted retinopathy of prematurity","volume":"12","author":"Hartnett","year":"2023","journal-title":"Ophthalmol Ther"},{"issue":"11","key":"10.1016\/j.xops.2026.101371_bib13","article-title":"Recurrence of retinopathy of prematurity following anti-vascular endothelial growth factor (Anti-VEGF) therapy: a systematic review and meta-analysis","volume":"16","author":"Dablouk","year":"2024","journal-title":"Cureus"},{"issue":"4","key":"10.1016\/j.xops.2026.101371_bib14","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1001\/jamaophthalmol.2014.5373","article-title":"Serum levels of vascular endothelial growth factor and related factors after intravitreous bevacizumab injection for retinopathy of prematurity","volume":"133","author":"Wu","year":"2015","journal-title":"JAMA Ophthalmol"},{"issue":"4","key":"10.1016\/j.xops.2026.101371_bib15","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1097\/IAE.0000000000001209","article-title":"Serum vascular endothelial growth factor after Bevacizumab or ranibizumab treatment for retinopathy of prematurity","volume":"37","author":"Wu","year":"2017","journal-title":"Retina"},{"issue":"5","key":"10.1016\/j.xops.2026.101371_bib16","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.ophtha.2016.12.025","article-title":"Anti-Vascular endothelial growth factor therapy for primary treatment of type 1 retinopathy of prematurity: a report by the American Academy of ophthalmology","volume":"124","author":"VanderVeen","year":"2017","journal-title":"Ophthalmology"},{"issue":"12","key":"10.1016\/j.xops.2026.101371_bib17","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1038\/sj.bjc.6603813","article-title":"Mechanisms of adverse effects of anti-VEGF therapy for cancer","volume":"96","author":"Kamba","year":"2007","journal-title":"Br J Cancer"},{"issue":"4","key":"10.1016\/j.xops.2026.101371_bib18","doi-asserted-by":"crossref","first-page":"e20153218","DOI":"10.1542\/peds.2015-3218","article-title":"Neurodevelopmental outcomes following Bevacizumab injections for retinopathy of prematurity","volume":"137","author":"Morin","year":"2016","journal-title":"Pediatrics"},{"issue":"2","key":"10.1016\/j.xops.2026.101371_bib19","doi-asserted-by":"crossref","first-page":"e20183537","DOI":"10.1542\/peds.2018-3537","article-title":"Neurodevelopmental outcomes of preterm infants with retinopathy of prematurity by treatment","volume":"144","author":"Natarajan","year":"2019","journal-title":"Pediatrics"},{"issue":"3","key":"10.1016\/j.xops.2026.101371_bib20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0230678","article-title":"Neurodevelopmental outcomes following intravitreal bevacizumab injection in Japanese preterm infants with type 1 retinopathy of prematurity","volume":"15","author":"Arima","year":"2020","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.xops.2026.101371_bib21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0148019","article-title":"Neurodevelopmental outcomes in infants with retinopathy of prematurity and Bevacizumab treatment","volume":"11","author":"Lien","year":"2016","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.xops.2026.101371_bib22","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/j.ophtha.2019.03.048","article-title":"Neurodevelopmental outcomes after intravitreal bevacizumab therapy for retinopathy of prematurity: a prospective case-control Study","volume":"126","author":"Fan","year":"2019","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.xops.2026.101371_bib23","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1111\/aos.17541","article-title":"Impact of anti-VEGF therapy versus laser therapy on mortality and treatment outcomes in retinopathy of prematurity: a systematic review and meta-analysis","volume":"104","author":"Wang","year":"2026","journal-title":"Acta Ophthalmol"},{"issue":"5","key":"10.1016\/j.xops.2026.101371_bib24","doi-asserted-by":"crossref","first-page":"2752","DOI":"10.3906\/sag-2101-76","article-title":"Effects of bevacizumab administration on the hypoxia - induced pulmonary hypertension rat model","volume":"51","author":"Demir","year":"2021","journal-title":"Turk J Med Sci"},{"issue":"11","key":"10.1016\/j.xops.2026.101371_bib25","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1001\/jamaophthalmol.2022.3788","article-title":"Pulmonary hypertension in preterm infants treated with laser vs anti-vascular endothelial growth factor therapy for retinopathy of prematurity","volume":"140","author":"Nitkin","year":"2022","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.xops.2026.101371_bib26","series-title":"D\u00e9cret n\u00b0 2021-848 du 29 juin 2021 relatif au traitement de donn\u00e9es \u00e0 caract\u00e8re personnel d\u00e9nomm\u00e9 \u00ab\u202fsyst\u00e8me national des donn\u00e9es de sant\u00e9","year":"2021"},{"issue":"6","key":"10.1016\/j.xops.2026.101371_bib27","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.therap.2024.05.003","article-title":"Use of the French National Health Data System (SNDS) in pharmacoepidemiology: a systematic review in its maturation phase","volume":"79","author":"Maillard","year":"2024","journal-title":"Therapie"},{"issue":"11-12","key":"10.1016\/j.xops.2026.101371_bib28","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1111\/apt.15504","article-title":"Safety of first year vaccination in children born to mothers with inflammatory bowel disease and exposed in utero to anti-TNF\u03b1 agents: a French nationwide population-based cohort","volume":"50","author":"Luu","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"issue":"11","key":"10.1016\/j.xops.2026.101371_bib29","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1038\/s41395-018-0176-7","article-title":"Continuous Anti-TNF\u03b1 use throughout pregnancy: possible complications for the mother but not for the fetus. A retrospective cohort on the French national health insurance database (EVASION)","volume":"113","author":"Luu","year":"2018","journal-title":"Am J Gastroenterol"},{"issue":"12","key":"10.1016\/j.xops.2026.101371_bib30","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1001\/jamaophthalmol.2018.3939","article-title":"Association of acute endophthalmitis with intravitreal injections of corticosteroids or anti-vascular growth factor agents in a nationwide Study in France","volume":"136","author":"Baudin","year":"2018","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.xops.2026.101371_bib31","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1471-2458-9-33","article-title":"Ecological association between a deprivation index and mortality in France over the period 1997 - 2001: variations with spatial scale, degree of urbanicity, age, gender and cause of death","volume":"9","author":"Rey","year":"2009","journal-title":"BMC Public Health"},{"issue":"1","key":"10.1016\/j.xops.2026.101371_bib32","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-74409-x","article-title":"Risk of early neurodevelopmental disorders associated with in utero exposure to valproate and other antiepileptic drugs: a nationwide cohort study in France","volume":"10","author":"Coste","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.xops.2026.101371_bib33","series-title":"Indicateurs de sant\u00e9 p\u00e9rinatale 2023\u202f: la mortinatalit\u00e9 reste stable en","year":"2023"},{"issue":"10","key":"10.1016\/j.xops.2026.101371_bib34","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/j.jgyn.2016.09.013","article-title":"\u00c9pid\u00e9miologie et facteurs de risque de la pr\u00e9maturit\u00e9","volume":"45","author":"Torchin","year":"2016","journal-title":"J de Gyn\u00e9cologie Obst\u00e9trique Biologie de la Reprod"},{"key":"10.1016\/j.xops.2026.101371_bib35","series-title":"Pr\u00e9maturit\u00e9. Des b\u00e9b\u00e9s qui arrivent trop t\u00f4t","year":"2023"},{"issue":"7","key":"10.1016\/j.xops.2026.101371_bib36","doi-asserted-by":"crossref","first-page":"281","DOI":"10.3345\/cep.2022.00822","article-title":"Neurodevelopmental outcomes of preterm infants","volume":"66","author":"Song","year":"2023","journal-title":"Clin Exp Pediatr"},{"key":"10.1016\/j.xops.2026.101371_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2021.101018","article-title":"Assessment and management of retinopathy of prematurity in the era of anti-vascular endothelial growth factor (VEGF)","volume":"88","author":"Tsai","year":"2022","journal-title":"Prog Retin Eye Res"},{"issue":"6","key":"10.1016\/j.xops.2026.101371_bib38","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1038\/s41372-020-00884-9","article-title":"Neurodevelopmental outcomes following bevacizumab treatment for retinopathy of prematurity: a systematic review and meta-analysis","volume":"41","author":"Kaushal","year":"2021","journal-title":"J Perinatol"},{"issue":"10","key":"10.1016\/j.xops.2026.101371_bib39","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1097\/IAE.0000000000001493","article-title":"Systemic pharmacokinetics and pharmacodynamics of intravitreal aflibercept, bevacizumab, and ranibizumab","volume":"37","author":"Avery","year":"2017","journal-title":"Retina"},{"issue":"6","key":"10.1016\/j.xops.2026.101371_bib40","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1001\/jamaophthalmol.2020.0334","article-title":"Short-term outcomes after very low-dose intravitreous bevacizumab for retinopathy of prematurity","volume":"138","author":"Wallace","year":"2020","journal-title":"JAMA Ophthalmol"},{"issue":"1","key":"10.1016\/j.xops.2026.101371_bib41","doi-asserted-by":"crossref","first-page":"e20193449","DOI":"10.1542\/peds.2019-3449","article-title":"Promoting optimal development: identifying infants and young children with developmental disorders through developmental surveillance and screening","volume":"145","author":"Lipkin","year":"2020","journal-title":"Pediatrics"},{"issue":"5 Pt 2","key":"10.1016\/j.xops.2026.101371_bib42","doi-asserted-by":"crossref","first-page":"11r","DOI":"10.1203\/PDR.0b013e318212faa0","article-title":"Preterm birth and childhood psychiatric disorders","volume":"69","author":"Johnson","year":"2011","journal-title":"Pediatr Res"}],"container-title":["Ophthalmology Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266691452600309X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266691452600309X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T16:10:22Z","timestamp":1790784622000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S266691452600309X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":42,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S266691452600309X"],"URL":"https:\/\/doi.org\/10.1016\/j.xops.2026.101371","relation":{},"ISSN":["2666-9145"],"issn-type":[{"value":"2666-9145","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neurodevelopmental Disorders in Infants Treated with Anti-VEGF Agents versus Laser Photocoagulation or Cryotherapy for Retinopathy of Prematurity","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xops.2026.101371","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Academy of Ophthalmology, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101371"}}